Unichem laboratories has received a credit rating reaffirmation from ICRA Limited, with the rating agency maintaining its [ICRA]A+ (Stable) rating for the pharmaceutical company's bank facilities totaling Rs. 180 crores. The company informed stock exchanges about this development through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rating Details and Facility Breakdown

ICRA's Rating Committee has reaffirmed the credit rating across multiple facility categories for Unichem Laboratories. The rating action covers both fund-based and non-fund based banking facilities along with unallocated limits.

Banking Partner Distribution

The company maintains banking relationships with multiple financial institutions for its rated facilities. The distribution of bank limits shows a diversified approach to banking partnerships.

Rating Timeline and Communication

The original rating was assigned on March 31, 2026, and the reaffirmation was communicated through ICRA's letter dated April 09, 2026. K Srikumar, Senior Vice President and Co Group Head at ICRA, signed the rating communication addressed to Sanjay Jain, Chief Financial Officer of Unichem Laboratories.

Regulatory Compliance and Surveillance

The rating will become due for surveillance within one year from the date of the rating communication letter. ICRA has reserved the right to review and revise the rating based on new information, changes in circumstances, or any developments that could impact the company's debt servicing capability. The rating agency has emphasized that any changes in terms, conditions, or size of the rated instruments would require a review of the ratings.

Unichem laboratories has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with stock exchanges on April 7, 2026, maintaining its regulatory compliance obligations.

Regulatory Compliance Details

The compliance certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's registrar and share transfer agent. The certificate, dated April 3, 2026, confirms adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were processed according to regulatory requirements. The registrar verified that securities were confirmed or rejected to depositories within prescribed timelines and that security certificates received for dematerialisation were properly mutilated and cancelled after due verification.

Stock Exchange Submission

Unichem Laboratories submitted the compliance certificate to both major Indian stock exchanges. The company's Head Legal & Company Secretary, Pradeep Gautam Bhandari, signed the submission letter addressed to BSE Limited and National Stock Exchange of India Limited.

This quarterly compliance certificate represents part of Unichem Laboratories' ongoing regulatory obligations as a listed pharmaceutical company, ensuring transparency in its depository and participant operations.